Recurrent Pericarditis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major recurrent pericarditis markets are expected to exhibit a CAGR of 4.08% during 2024-2034.
The recurrent pericarditis market has been comprehensively analyzed in IMARC's new report titled "Recurrent Pericarditis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Recurrent pericarditis is a medical condition characterized by inflammation of the pericardium, a thin, double-layered sac surrounding the heart. This condition is marked by episodes of chest pain, which can range from moderate discomfort to severe, sharp pain. The pain is often exacerbated by deep breathing, coughing, or changes in body position and may radiate to the neck, shoulder, or back. This disease can lead to significant impairment of daily activities and reduced quality of life for patients. The diagnosis of recurrent pericarditis involves a combination of clinical evaluation, medical history assessment, and diagnostic tests. The healthcare provider will carefully analyze the patient's symptoms to distinguish them from various other cardiac and non-cardiac conditions that might present with similar signs. Physical examination findings, such as a characteristic pericardial friction rub, may also aid in the diagnosis. Laboratory tests, including markers of inflammation (like C-reactive protein or erythrocyte sedimentation rate), may also be utilized to support the diagnosis of recurrent pericarditis.
The increasing cases of viral infections that can induce an immune response affecting the pericardium are primarily driving the recurrent pericarditis market. In addition to this, the inflating utilization of colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, etc., as efficacious remedies to alleviate symptoms and prevent recurrences is also creating a positive outlook for the market. Moreover, the widespread adoption of pericardial drainage procedures, such as pericardiocentesis, to manage excess fluid accumulation and reduce pressure on the heart is further bolstering the market growth. Apart from this, the rising usage of cardiac rehabilitation programs on account of their several benefits, like enhancing cardiovascular fitness, restoring functional capacity, and improving the overall quality of life for people suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced imaging modalities, such as cardiac magnetic resonance imaging (MRI) and computed tomography (CT) scans, since they help in more accurate and timely diagnosis of the condition, is also augmenting the market growth. Furthermore, the escalating demand for targeted biological therapies, which are specifically designed to inhibit key molecules and pathways involved in the inflammatory response, leading to better control of the inflammation, is expected to drive the recurrent pericarditis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the recurrent pericarditis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for recurrent pericarditis and represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the recurrent pericarditis market in any manner.
Recent Developments:
In February 2024, Cardiol Therapeutics Inc. successfully enrolled patients for its Phase II open-label pilot study, titled "MAvERIC-Pilot." This study is focused on evaluating the safety, tolerance, and efficacy of CardiolRx in patients suffering from recurrent pericarditis.
In December 2023, R-Pharm Overseas, Inc. commenced a phase 2 clinical trial for RPH-104, aiming to assess the efficacy and safety of this treatment in patients with recurrent pericarditis.
In November 2023, Cardiol Therapeutics Inc. enrolled over 50% of its targeted patient population in its Phase 2 study for the treatment of patients with recurrent pericarditis.
Key Highlights:
15-30% of the patients having pericarditis will experience recurrent pericarditis at some point in their life.
Males are more likely to develop recurrent pericarditis than females, furthermore, males in the age group of 20-50 years are more susceptible to the disease and experience repeated episodes of pericarditis.
Three or more episodes of recurring pericarditis are experienced by around 6% of patients with a median duration of the disease activity spanning between 2.8-4.7 years.
Drugs:
Arcalyst (Rilonacept), developed by Kiniksa Pharmaceuticals, is an interleukin-1 blocker. The drug is administered subcutaneously and is indicated for treating Recurrent Pericarditis (RP) and lowering the risk of recurrence in patients aged 12 years and above.
CardiolRx is a pharmaceutical solution designed for oral administration, enriched with cannabidiol, and tailored for therapeutic purposes. Its mode of action focuses on addressing diverse inflammatory pathways, predominantly by inhibiting the activation of the NLRP3 inflammasome.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the recurrent pericarditis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the recurrent pericarditis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current recurrent pericarditis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the recurrent pericarditis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the recurrent pericarditis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the recurrent pericarditis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of recurrent pericarditis across the seven major markets?
What is the number of prevalent cases (2018-2034) of recurrent pericarditis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of recurrent pericarditis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with recurrent pericarditis across the seven major markets?
What is the size of the recurrent pericarditis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of recurrent pericarditis?
What will be the growth rate of patients across the seven major markets?
Recurrent Pericarditis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for recurrent pericarditis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the recurrent pericarditis market?
What are the key regulatory events related to the recurrent pericarditis market?
What is the structure of clinical trial landscape by status related to the recurrent pericarditis market?
What is the structure of clinical trial landscape by phase related to the recurrent pericarditis market?
What is the structure of clinical trial landscape by route of administration related to the recurrent pericarditis market?
The recurrent pericarditis market has been comprehensively analyzed in IMARC's new report titled "Recurrent Pericarditis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Recurrent pericarditis is a medical condition characterized by inflammation of the pericardium, a thin, double-layered sac surrounding the heart. This condition is marked by episodes of chest pain, which can range from moderate discomfort to severe, sharp pain. The pain is often exacerbated by deep breathing, coughing, or changes in body position and may radiate to the neck, shoulder, or back. This disease can lead to significant impairment of daily activities and reduced quality of life for patients. The diagnosis of recurrent pericarditis involves a combination of clinical evaluation, medical history assessment, and diagnostic tests. The healthcare provider will carefully analyze the patient's symptoms to distinguish them from various other cardiac and non-cardiac conditions that might present with similar signs. Physical examination findings, such as a characteristic pericardial friction rub, may also aid in the diagnosis. Laboratory tests, including markers of inflammation (like C-reactive protein or erythrocyte sedimentation rate), may also be utilized to support the diagnosis of recurrent pericarditis.
The increasing cases of viral infections that can induce an immune response affecting the pericardium are primarily driving the recurrent pericarditis market. In addition to this, the inflating utilization of colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, etc., as efficacious remedies to alleviate symptoms and prevent recurrences is also creating a positive outlook for the market. Moreover, the widespread adoption of pericardial drainage procedures, such as pericardiocentesis, to manage excess fluid accumulation and reduce pressure on the heart is further bolstering the market growth. Apart from this, the rising usage of cardiac rehabilitation programs on account of their several benefits, like enhancing cardiovascular fitness, restoring functional capacity, and improving the overall quality of life for people suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced imaging modalities, such as cardiac magnetic resonance imaging (MRI) and computed tomography (CT) scans, since they help in more accurate and timely diagnosis of the condition, is also augmenting the market growth. Furthermore, the escalating demand for targeted biological therapies, which are specifically designed to inhibit key molecules and pathways involved in the inflammatory response, leading to better control of the inflammation, is expected to drive the recurrent pericarditis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the recurrent pericarditis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for recurrent pericarditis and represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the recurrent pericarditis market in any manner.
Recent Developments:
In February 2024, Cardiol Therapeutics Inc. successfully enrolled patients for its Phase II open-label pilot study, titled "MAvERIC-Pilot." This study is focused on evaluating the safety, tolerance, and efficacy of CardiolRx in patients suffering from recurrent pericarditis.
In December 2023, R-Pharm Overseas, Inc. commenced a phase 2 clinical trial for RPH-104, aiming to assess the efficacy and safety of this treatment in patients with recurrent pericarditis.
In November 2023, Cardiol Therapeutics Inc. enrolled over 50% of its targeted patient population in its Phase 2 study for the treatment of patients with recurrent pericarditis.
Key Highlights:
15-30% of the patients having pericarditis will experience recurrent pericarditis at some point in their life.
Males are more likely to develop recurrent pericarditis than females, furthermore, males in the age group of 20-50 years are more susceptible to the disease and experience repeated episodes of pericarditis.
Three or more episodes of recurring pericarditis are experienced by around 6% of patients with a median duration of the disease activity spanning between 2.8-4.7 years.
Drugs:
Arcalyst (Rilonacept), developed by Kiniksa Pharmaceuticals, is an interleukin-1 blocker. The drug is administered subcutaneously and is indicated for treating Recurrent Pericarditis (RP) and lowering the risk of recurrence in patients aged 12 years and above.
CardiolRx is a pharmaceutical solution designed for oral administration, enriched with cannabidiol, and tailored for therapeutic purposes. Its mode of action focuses on addressing diverse inflammatory pathways, predominantly by inhibiting the activation of the NLRP3 inflammasome.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the recurrent pericarditis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the recurrent pericarditis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current recurrent pericarditis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the recurrent pericarditis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the recurrent pericarditis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the recurrent pericarditis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of recurrent pericarditis across the seven major markets?
What is the number of prevalent cases (2018-2034) of recurrent pericarditis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of recurrent pericarditis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with recurrent pericarditis across the seven major markets?
What is the size of the recurrent pericarditis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of recurrent pericarditis?
What will be the growth rate of patients across the seven major markets?
Recurrent Pericarditis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for recurrent pericarditis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the recurrent pericarditis market?
What are the key regulatory events related to the recurrent pericarditis market?
What is the structure of clinical trial landscape by status related to the recurrent pericarditis market?
What is the structure of clinical trial landscape by phase related to the recurrent pericarditis market?
What is the structure of clinical trial landscape by route of administration related to the recurrent pericarditis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RECURRENT PERICARDITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RECURRENT PERICARDITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RECURRENT PERICARDITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 RECURRENT PERICARDITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RECURRENT PERICARDITIS - UNMET NEEDS
10 RECURRENT PERICARDITIS - KEY ENDPOINTS OF TREATMENT
11 RECURRENT PERICARDITIS - MARKETED PRODUCTS
11.1 List of Recurrent Pericarditis Marketed Drugs Across the Top 7 Markets
11.1.1 Arcalyst (Rilonacept) - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RECURRENT PERICARDITIS - PIPELINE DRUGS
12.1 List of Recurrent Pericarditis Pipeline Drugs Across the Top 7 Markets
12.1.1 Goflikicept - TRPHARM
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CardiolRx - Cardiol Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. RECURRENT PERICARDITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RECURRENT PERICARDITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RECURRENT PERICARDITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Recurrent Pericarditis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Recurrent Pericarditis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Recurrent Pericarditis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Recurrent Pericarditis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Recurrent Pericarditis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Recurrent Pericarditis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Recurrent Pericarditis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Recurrent Pericarditis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Recurrent Pericarditis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Recurrent Pericarditis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Recurrent Pericarditis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Recurrent Pericarditis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Recurrent Pericarditis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Recurrent Pericarditis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Recurrent Pericarditis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Recurrent Pericarditis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Recurrent Pericarditis - Access and Reimbursement Overview
16 RECURRENT PERICARDITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RECURRENT PERICARDITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RECURRENT PERICARDITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RECURRENT PERICARDITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RECURRENT PERICARDITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RECURRENT PERICARDITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 RECURRENT PERICARDITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RECURRENT PERICARDITIS - UNMET NEEDS
10 RECURRENT PERICARDITIS - KEY ENDPOINTS OF TREATMENT
11 RECURRENT PERICARDITIS - MARKETED PRODUCTS
11.1 List of Recurrent Pericarditis Marketed Drugs Across the Top 7 Markets
11.1.1 Arcalyst (Rilonacept) - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RECURRENT PERICARDITIS - PIPELINE DRUGS
12.1 List of Recurrent Pericarditis Pipeline Drugs Across the Top 7 Markets
12.1.1 Goflikicept - TRPHARM
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CardiolRx - Cardiol Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. RECURRENT PERICARDITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RECURRENT PERICARDITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RECURRENT PERICARDITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Recurrent Pericarditis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Recurrent Pericarditis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Recurrent Pericarditis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Recurrent Pericarditis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Recurrent Pericarditis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Recurrent Pericarditis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Recurrent Pericarditis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Recurrent Pericarditis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Recurrent Pericarditis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Recurrent Pericarditis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Recurrent Pericarditis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Recurrent Pericarditis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Recurrent Pericarditis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Recurrent Pericarditis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Recurrent Pericarditis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Recurrent Pericarditis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Recurrent Pericarditis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Recurrent Pericarditis - Access and Reimbursement Overview
16 RECURRENT PERICARDITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RECURRENT PERICARDITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RECURRENT PERICARDITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
